JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status
Payandeh, Mehrdad; Shahriari-Ahmadi, Ali; Sadeghi, Masoud; Sadeghi, Edris;
  PDF(new window)
 Abstract
Background: Overexpression or amplification of human epidermal growth factor receptor-2 (HER2) is associated with grade of malignancy and a poor prognosis in breast cancer (BC). The aim of this study was to evaluate of value of HER2 as a prognostic marker, and to analyze associations with common histopathological parameters in BC cases. Materials and Methods: Between of 2007 to 2014, 260 patients with BC referred to Oncology Clinic provided cancer tissue samples which underwent immunohistochemistry (IHC) for markers. ER and PR positivity was defined as positive tumor cells with nuclear staining. HER2-positive was defined as either HER2 gene amplification by fluorescent in situ hybridization (FISH) or scored as 3+ by IHC. For HER2 (2+), FISH was performed to determine HER2 positivity. Results: The mean age at diagnosis for the patients with HER2-negative was significantly higher than in HER2-positive cases. Also, there were significant correlations between histological grade, nuclear grade, lymph node metastasis, tumor size, ER status, PR status, p53 overexpression and Ki-67 index with HER2 expression. HER2-negative lesions were of higher grade and more likely to be ER-negative, PR-negative, p53-positive, lymph node metastasis, with a tumor size<2cm and also as compared to the HER2-positive group. Conclusions: Contrary to the results of other studies, HER2-positive tumors in our study had a lower Ki-67 index and were p53-positive. Also, Ki-67 proliferation index in more studies was associated with p53-positive.Therefore, tumors which are HER2-positive and have a Ki- had a more aggressive behavior compared to HER2-positive and Ki-67<20% lesions.
 Keywords
Breast cancer;HER2;Ki-67;immunohistochemisty;FISH;Western Iran;
 Language
English
 Cited by
1.
Androgen Receptor Expression and its Correlation with Other Risk Factors in Triple Negative Breast Cancers: a Report from Western Iran,;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 7, pp.3321-3324 crossref(new window)
1.
Machine learning approaches to decipher hormone and HER2 receptor status phenotypes in breast cancer, Briefings in Bioinformatics, 2017, 1477-4054  crossref(new windwow)
 References
1.
Ahmadi AS, Mahdipour L, Payandeh M, et al (2015). Epidemiology, pathology and histochemistry features in women with breast cancer. Am J Cancer Prev, 3, 54-7.

2.
Camerini A, Donati S, Viacava P, et al (2011). Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res, 30, 38. crossref(new window)

3.
Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. crossref(new window)

4.
el AT, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50.

5.
Fountzilas G, Valavanis C, Kotoula V, et al (2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med, 10, 10. crossref(new window)

6.
Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. crossref(new window)

7.
Hayashi N, Niikura N, Masuda N, et al (2015). Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat, 149, 277-84. crossref(new window)

8.
Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. crossref(new window)

9.
Kai K, Nishimura R, Arima N, et al (2006). p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol, 11, 426-33. crossref(new window)

10.
Lee DS, Kim SH, Suh YJ, et al (2011). Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol, 41, 854-66. crossref(new window)

11.
Li FY, Wu SG, Zhou J, et al (2014). Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One, 9, 87264. crossref(new window)

12.
Menard S, Fortis S, Castiglioni F, et al (2001). HER2 as a prognostic factor in breast cancer. Oncol, 61, 67-72. crossref(new window)

13.
Nishimura R, Osako T, Okumura Y, et al (2010). Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med, 1, 747-54. crossref(new window)

14.
Patnayak R, Jena A, Rukmangadha N, et al (2015). Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol, 36, 117-22. crossref(new window)

15.
Payandeh M, Khodarahmi R, Sadeghi M, et al (2015a). Appearance of acute myelogenous leukemia (AML) in a patient with breast cancer after adjuvant chemotherapy: case report and review of the literature. Iran J Cancer Prev, 8, 125-8.

16.
Payandeh M, Sadeghi M, Sadeghi E, et al (2015b). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. crossref(new window)

17.
Shokouh TZ, Ezatollah A, Barand P (2015). Interrelationships Between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study. Med (Baltimore), 94, 1359. crossref(new window)

18.
Swede H, Moysich KB, Freudenheim JL, et al (2001). Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev, 25, 511-9.

19.
Wiesner FG, Magener A, Fasching PA, (2009). Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 18, 135-41. crossref(new window)

20.
Yamamoto M, Hosoda M, Nakano K, et al (2014). p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci, 105, 81-8. crossref(new window)

21.
Yarden Y (2001). Biology of HER2 and its importance in breast cancer. Oncol, 61, 1-13.